Form 4: Black Diamond Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Shannon Campbell acquired stock options in Black Diamond Therapeutics, Inc. on April 10, 2024.
Summary
- On April 10, 2024, Shannon Campbell, a director of Black Diamond Therapeutics, Inc., acquired stock options.
- The stock options grant the right to buy 61,100 shares of common stock at an exercise price of $4.98.
- The options vest in 36 equal monthly installments starting May 10, 2024, contingent upon continued service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the director.
Key Dates
| Date | Description |
|---|---|
| 04/10/2024 | Date of stock option grant |
| 05/10/2024 | First vesting date of the stock options |
| 04/09/2034 | Expiration date of the stock options |
| 04/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.